- Home
- BPMC
as 06-20-2025 4:00pm EST
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 5.8B | IPO Year: | 2015 |
| Target Price: | $127.82 | AVG Volume (30 days): | 6.4M |
| Analyst Decision: | Buy | Number of Analysts: | 20 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.45 | EPS Growth: | N/A |
| 52 Week Low/High: | $73.04 - $128.34 | Next Earning Date: | 07-31-2025 |
| Revenue: | $562,121,000 | Revenue Growth: | 99.19% |
| Revenue Growth (this year): | 44.46% | Revenue Growth (next year): | 32.78% |
Stock Insider Trading Activity of Blueprint Medicines Corporation (BPMC)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Carter Percy H. | BPMC | CHIEF SCIENTIFIC OFFICER | Jun 3 '25 | Sell | $127.88 | 2,659 | $340,032.92 | 54,206 | |
| Albers Jeffrey W. | BPMC | Director | May 27 '25 | Sell | $101.48 | 5,000 | $505,691.50 | 146,630 | |
| Rossi Christina | BPMC | CHIEF OPERATING OFFICER | May 19 '25 | Sell | $100.84 | 2,274 | $228,557.31 | 66,188 | |
| Rossi Christina | BPMC | CHIEF OPERATING OFFICER | May 5 '25 | Sell | $102.28 | 2,274 | $231,386.14 | 66,188 | |
| Hurley Ariel | BPMC | PRINCIPAL ACCOUNTING OFFICER | May 5 '25 | Sell | $103.62 | 2,752 | $283,818.52 | 16,944 | |
| Haviland Kate | BPMC | CHIEF EXECUTIVE OFFICER | Apr 1 '25 | Sell | $86.88 | 2,498 | $216,460.72 | 167,229 | |
| Rossi Christina | BPMC | CHIEF OPERATING OFFICER | Mar 24 '25 | Sell | $95.02 | 2,274 | $216,075.48 | 66,188 |
Latest Blueprint Medicines Corporation News
BPMC Breaking Stock News: Dive into BPMC Ticker-Specific Updates for Smart Investing
Simply Wall St.
20 hours ago
Exploring 3 High Growth Tech Stocks in the US Market
Simply Wall St.
2 days ago
Exploring Three High Growth Tech Stocks In The US Market
MT Newswires
4 days ago
Wells Fargo Downgrades Blueprint Medicines to Equalweight From Overweight, Price Target is $129
Simply Wall St.
4 days ago
Exploring High Growth Tech Opportunities in US Markets
PR Newswire
8 days ago
Blueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT®/AYVAKYT® (avapritinib) Treatment at 2025 EHA and EAACI Congresses
Zacks
15 days ago
Why Is Acadia (ACAD) Up 26.1% Since Last Earnings Report?
MT Newswires
15 days ago
Blueprint Medicines Insider Sold Shares Worth $340,033, According to a Recent SEC Filing
MT Newswires
16 days ago
UBS Adjusts Price Target on Blueprint Medicines to $129 From $88, Maintains Neutral Rating
Compare BPMC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BPMC Blueprint Medicines Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.